1-3 of 3
Hilde Rosing, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

SAKK 65/08: A Phase I Dose Escalation Study of Bortezomib in Combination with Nelfinavir in Patients with Advanced Hematologic Malignancies

Christoph Driessen, MD, Jürgen Bader, Marianne Kraus, PhD, Markus Jörger, MD PhD, Hilde Rosing, PhD, Gregoire Berthod, MD, Felicitas Hitz, MD, Catherine Berset, PhD, Alexandros Xyrafas, Hanne Hawle, MD, Hermann S Overkleeft, PhD, Christiana Sessa, MD, Alwin Huitema, PhD, Ulrich JM Mey, Thomas Pabst, MD, Roger von Moos, MD, Dagmar Hess, MD
Journal: Blood
Blood (2014) 124 (21): 4747.
https://doi.org/10.1182/blood.V124.21.4747.4747
Published: 2014
Journal Articles

SAKK 65/08: A Phase I Trial of the HIV Protease Inhibitor Nelfinavir in Combination with Bortezomib Identifies Nelfinavir As FDA Approved, Oral Drug that Inhibits the Proteasome and Induces Proteotoxic Stress in Vivo and has Potential Antimyeloma Activity.

Christoph Driessen, MD, Dagmar Hess, MD, Thomas Pabst, MD, Sarah R Haile, Markus Joerger, MD, Roger von Moos, MD, Catherine Berset, Susanne Crowe, Hilde Rosing, PhD, Hermen S Overkleeft, Christiana Sessa, Marianne Kraus
Journal: Blood
Blood (2012) 120 (21): 2956.
https://doi.org/10.1182/blood.V120.21.2956.2956
Published: 2012
Journal Articles

An Open-Label Phase I Pharmacokinetic Study of [ 14 c] Bendamustine in Patients with Relapsed or Refractory Malignancy

Anne-Charlotte Dubbelman, MSc, Hilde Rosing, PhD, Mona Darwish, PhD, Denise D'Andrea, MD, Mary Bond, MS, MBA, Edward T. Hellriegel, PhD, Jos H. Beijnen, PharmD, PhD, Jan H. M. Schellens, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 2476.
https://doi.org/10.1182/blood.V118.21.2476.2476
Published: 2011